Interestingly, zoledronic acid is known to raise the cytotoxic activity of Vγ9Vδ2 T-cells against osteosarcoma cells, in particular against cells pretreated with the anti-Her2 Trastuzumab antibody [54]. Here, ERBB2 is linked to osteosarcoma.